Key result
Discharge mRSI ≥1.25 is linked to ~51% lower 60-day mortality vs mRSI 1-1.25 in HFrEF.
Why the study?
Increased blood pressure and decreased heart rate reflect stabilization in acute heart failure, prompting assessment of how these in-hospital changes correlate with outcomes in HFrEF.
Does the modified reverse shock index (mRSI) predict early mortality in patients hospitalized for HFrEF?
Cohort (n=2,697)
Does the modified reverse shock index (mRSI) predict early mortality in patients hospitalized for HFrEF?
Hazard Ratio: 0.49 (95% CI 0.31–0.77)
p-value: p=<0.001
The modified reverse shock index (mRSI) at discharge serves as a significant predictor of 60-day and 180-day all-cause mortality in patients hospitalized for HFrEF.
May aid post-discharge risk stratification in HFrEF; hypothesis-generating and requires prospective validation.
AIMS: Increased blood pressure (BP) and decreased heart rate (HR) are signs of stabilization in patients admitted for acute HF. Changes in BP and HR during admission and their correlation with outcomes were assessed in hospitalized patients with heart failure (HF) with reduced ejection fraction (HFrEF). METHODS: A novel modified reverse shock index (mRSI), defined as the ratio between changes in systolic BP and HR during admission, was devised, and its prognostic value in the early outcomes of acute HF was assessed using the Korean Acute HF registry. RESULTS: Among 2697 patients with HFrEF (mean age 65.8 ± 14.9 years, 60.6% males), patients with mRSI ≥1.25 at discharge were significantly younger and were more likely to have de novo HF. An mRSI ≥1.25 was associated with a significantly lower incidence of 60-day and 180-day all-cause mortality [hazard ratio (HR) 0.49, 95% confidence interval (CI) 0.31-0.77; HR 0.62, 95% CI 0.45-0.85, respectively], compared with 1 ≤ mRSI < 1.25 (all P < 0.001). Conversely, an mRSI <0.75 was associated with a significantly higher incidence of 60-day and 180-day all-cause mortality (adjusted HR 2.08, 95% CI 1.19-3.62; HR 2.24, 95% CI 1.53-3.27; all P < 0.001). The benefit associated with mRSI ≥1.25 was consistent in sub-group analyses. The correlation of mRSI and outcomes were also consistent regardless of admission SBP, presence of atrial fibrillation, or use of beta blockers at discharge. CONCLUSIONS: In patients hospitalized for HFrEF, the mRSI was a significant predictor of early outcomes. The mRSI could be used as a tool to assess patient status and guide physicians in treating patients with HFrEF.
No takes yet. Share an insight, caveat, or question.
Oh et al. (2022) conducted a cohort in Heart failure with reduced ejection fraction (HFrEF) (n=2,697). Modified reverse shock index (mRSI) ≥1.25 vs. 1 ≤ mRSI < 1.25 was evaluated on 60-day all-cause mortality (HR 0.49, 95% CI 0.31-0.77, p=<0.001). An mRSI ≥1.25 at discharge was associated with a significantly lower incidence of 60-day all-cause mortality compared with 1 ≤ mRSI < 1.25 in patients with HFrEF (HR 0.49; 95% CI 0.31-0.77; P<0.001).